Menu

News

Select Year
07.08.2025
Alpha Cognition to Present ZUNVEYL® (Benzgalantamine) Study Data at Alzheimer’s Association International Conference
07.01.2025
Alpha Cognition Announces Positive Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
05.15.2025
Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
04.10.2025
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
03.31.2025
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
03.20.2025
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
03.19.2025
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
01.14.2025
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
01.08.2025
Alpha Cognition Announces a $44 Million Exclusive Licensing Agreement for the Development and Commercialization of ZUNVEYL (benzgalantamine), an FDA-approved treatment for Mild-to-Moderate Alzheimer’s Disease, in China
01.06.2025
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
12.16.2024
Alpha Cognition Announces Partial Exercise of Over-Allotment Option
12.12.2024
Alpha Cognition Announces Voluntary Delisting from CSE
12.11.2024
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
11.12.2024
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
10.21.2024
Alpha Cognition Announces Appointment of VP Finance and Accounting
10.15.2024
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
08.19.2024
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
08.13.2024
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
07.29.2024
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
04.03.2024
Alpha Cognition Announces Fourth Quarter and Full Year 2023 Results and Provides Corporate Update
03.20.2024
Alpha Cognition to Present at the Emerging Growth Conference on April 3, 2024 at 12:00pm EST
03.01.2024
Alpha Cognition to Present at the Life Science Investor Forum March 7th
02.22.2024
Alpha Cognition files U.S. Patent Application covering an ALPHA-1062 oral formulation to treat Mild to Moderate Alzheimer’s Disease
02.12.2024
Alpha Cognition Provides Business Update
01.19.2024
Alpha Cognition Announces Final Closing Of Private Placement Offering And Completion Of The Overalloment
12.22.2023
Alpha Cognition Announces Fourth Closing Of Private Placement And Continuation Of The Offering
12.07.2023
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
12.04.2023
Alpha Cognition Announces Amended Terms Of Private Placement And Continuation Of The Offering
11.28.2023
Alpha Cognition Announces Third Quarter and Nine Months Ended September 30, 2023, Results and Provides Corporate Update
11.08.2023
Alpha Cognition Announces Third Closing Of Private Placement And Continuation Of The Offering
10.16.2023
Alpha Cognition Announces Second Closing Of Private Placement And Continuation Of The Offering
09.27.2023
Alpha Cognition Announces Submission of New Drug Application to the FDA for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
08.22.2023
Alpha Cognition Announces Second Quarter and Six Months Ended 2023 Results and Provides Corporate Update
08.10.2023
Alpha Cognition Receives Notice of Allowance for U.S. Patent Application covering use of ALPHA-1062 for Mild to Moderate Alzheimer’s Disease
06.07.2023
Alpha Cognition receives Army Medical Research Grant for Study on mild Traumatic Brain Injury (mTBI) from Blast Induced Functional Deficit and Brain Pathology
05.30.2023
Alpha Cognition Announces First Quarter 2023 Results and Provides Corporate Update
05.19.2023
Alpha Cognition Launches $6.5 Million Private Placement
04.28.2023
CSE Bulletin: New Listing - Alpha Cognition Inc. (ACOG, ACOG.WT)
04.27.2023
Alpha Cognition Announces CSE Listing and TSXV De-listing
03.16.2023
Alpha Cognition Closes Private Placement
03.08.2023
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
03.06.2023
Alpha Cognition Provides Private Placement Update
02.16.2023
Alpha Cognition Closes First Tranche Of Private Placement
02.08.2023
Alpha Cognition Announces $6.8 Million Private Placement
01.19.2023
Alpha Cognition Announces Cancelation and Grant of Stock Options
01.06.2023
Alpha Cognition Announces the Resignation of Chief Medical Officer Cedric O’Gorman, MD
11.28.2022
Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
08.25.2022
Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
08.22.2022
Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
06.22.2022
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
06.15.2022
Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602
06.15.2022
Alpha Cognition to Webcast Live at VirtualInvestorConferences.com June 23rd
06.13.2022
Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
05.31.2022
Alpha Cognition Announces First Quarter 2022 Results and Company Update
04.28.2022
Alpha Cognition Announces Fourth Quarter and Full Year 2021 Results and Company Update
04.12.2022
Alpha Cognition Announces Change of CFO, Grant of Stock Options and Addition to the Board of Directors
03.29.2022
Alpha Cognition Announces Positive Data from Pre-Clinical Studies of ALPHA-0602 (Progranulin) for Amyotrophic Lateral Sclerosis (ALS)
02.22.2022
Alpha Cognition Announces Positive Neuroprotection Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury
01.03.2022
Alpha Cognition Announces Participation in January Investor Conferences
12.27.2021
Alpha Cognition Announces Director Change and Stock Option Grant
12.06.2021
Alpha Cognition Announce Data from Pre-Clinical Study of ALPHA-1062 for Traumatic Brain Injury
12.02.2021
Alpha Cognition Appoints Cedric O'Gorman, M.D., MBA as Chief Medical Officer
11.30.2021
Alpha Cognition Reports Third Quarter of Fiscal 2021 Results
10.08.2021
Alpha Cognition to Present at LD Micro Main Event
10.07.2021
Alpha Cognition Provides CEO Update
10.01.2021
Alpha Cognition Announces Formation and Members of Scientific Advisory Board and Investor Relations Agreements
10.01.2021
Alpha Cognition Announces Closing of $14.4 Million Public Offering
09.29.2021
Alpha Cognition Updates Anticipated Closing Date of Public Offering
09.23.2021
Alpha Cognition Announces Pricing of Public Offering
09.22.2021
Alpha Cognition Announces Overnight Marketed Offering
09.11.2021
Alpha Cognition, Focused on Neurodegenerative Diseases, CEO Clip Video
09.09.2021
Alpha Cognition to Webcast Live at Life Sciences Investor Forum September 16th
09.07.2021
Alpha Cognition Announces the Acceptance of its US FDA Investigational New Drug Application (IND) for Lead Candidate, ALPHA-1062 for Mild to Moderate Alzheimer's Disease
09.01.2021
Alpha Cognition to Participate at the H.C. Wainwright 23rd Annual Global Investment Conference September 13-15, 2021
08.20.2021
Alpha Cognition Receives Approval to Commence Trading on the OTCQB
06.03.2021
Alpha Cognition to Host Virtual R&D Day on June 22, 2021
05.04.2021
Alpha Cognition Appoints Lauren D'Angelo as Chief Commercial Officer to Drive Strategic Growth
04.30.2021
Alpha Cognition to Host Investor Webcast on May 6th, 2021
04.27.2021
Alpha Cognition Announces Ms. Colleen Johns as SVP, Product Development Further Strengthening the ALPHA-1062 Drug Commercialization Team
04.12.2021
Alpha Cognition Announces Mr. Michael McFadden as Chief Executive Officer and Realignment of Leadership Team for Next Stage of ALPHA-1062 Drug Development
03.23.2021
Alpha Cognition Presenting at the Benzinga Biotech Small Cap Conference
03.22.2021
Alpha Cognition Announces Closing of Qualifying Transaction
03.08.2021
Crystal Bridge Provides Transaction Update
12.04.2020
Crystal Bridge Announces Receipt by Alpha Cognition of Japanese Patent for Alzheimer Drug Alpha-1062 and Announces Private Placement Updates
10.28.2020
Crystal Bridge Enters into Arrangement Agreement with Alpha Cognition, Announces up to $13 Million Private Placement
07.14.2020
Crystal Bridge Enterprises Announces Letter of Intent for Qualifying Transaction with Alpha Cognition Inc.
06.08.2020
Alpha Cognition, Inc. Attends the BIO Digital Partnering Event This Week
05.12.2020
Alpha Cognition Inc. Announces Granted EU Patents and Orphan Drug Designation for its Progranulin Platform
04.30.2020
Alpha Cognition Inc. Receives FDA/PMDA Regulatory Guidance for Alpha-1062 Alzheimer's Therapy
04.21.2020
Linical and Alpha Cognition Announce Strategic Partnership to Position Alpha- 1062 for Approval in the Unites States and Japan Alzheimer's Markets
04.09.2020
Alpha Cognition Inc. Name Change
View Video
Read More

Latest News

View All
View All

TSX-V: ACI

15 min delay
Last$9.81
Change$0.13
Open9.78
Vol543872
High9.91
Low9.67
Stock Information